These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 38837909)

  • 1. Dual-Targeted Self-Adjuvant Heterocyclic Lipidoid@Polyester Hybrid Nanovaccines for Boosting Cancer Immunotherapy.
    Liu Z; Liu B; Feng Y; Zhao L; Wang Q; He H; Yin T; Zhang Y; Yang L; Gou J; Tang X
    ACS Nano; 2024 Jun; 18(24):15557-15575. PubMed ID: 38837909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucosylated Nanovaccines for Dendritic Cell-Targeted Antigen Delivery and Amplified Cancer Immunotherapy.
    Liu J; Cui Y; Cabral H; Tong A; Yue Q; Zhao L; Sun X; Mi P
    ACS Nano; 2024 Sep; 18(37):25826-25840. PubMed ID: 39196858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-responsive PEG-lipid polyester nanoparticles for siRNA and vaccine delivery elicit anti-cancer immune responses by modulating tumor microenvironment.
    Liu Z; Zhao L; Feng Y; Wang Q; Dong N; Zhang Y; Yin T; He H; Tang X; Gou J; Yang L
    Biomater Sci; 2023 Sep; 11(19):6619-6634. PubMed ID: 37608695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists.
    Baljon JJ; Kwiatkowski AJ; Pagendarm HM; Stone PT; Kumar A; Bharti V; Schulman JA; Becker KW; Roth EW; Christov PP; Joyce S; Wilson JT
    ACS Nano; 2024 Mar; 18(9):6845-6862. PubMed ID: 38386282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetically Engineered Cytomembrane Nanovaccines for Cancer Immunotherapy.
    Pan Y; Wu X; Liu L; Zhao C; Zhang J; Yang S; Pan P; Huang Q; Zhao XZ; Tian R; Rao L
    Adv Healthc Mater; 2024 May; 13(13):e2400068. PubMed ID: 38320299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stimulator of Interferon Genes-Activated Biomimetic Dendritic Cell Nanovaccine as a Chemotherapeutic Booster to Enhance Systemic Fibrosarcoma Treatment.
    Wang Z; Miao F; Gu L; Zhang R; Ma Y; Li Y; Zheng J; Lin Z; Gao Y; Huang L; Shen Y; Wu T; Luo F; Li W
    ACS Nano; 2024 Sep; 18(35):24219-24235. PubMed ID: 39172516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA Origami Functions as a Self-Adjuvanted Nanovaccine Platform for Cancer Immunotherapy.
    Yip T; Qi X; Yan H; Chang Y
    ACS Nano; 2024 Feb; 18(5):4056-4067. PubMed ID: 38270089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monophosphoryl lipid A-assembled nanovaccines enhance tumor immunotherapy.
    Li R; Hao Y; Pan W; Wang W; Min Y
    Acta Biomater; 2023 Nov; 171():482-494. PubMed ID: 37708924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineering Polymeric Prodrug Nanoplatform for Vaccination Immunotherapy of Cancer.
    Zhou L; Hou B; Wang D; Sun F; Song R; Shao Q; Wang H; Yu H; Li Y
    Nano Lett; 2020 Jun; 20(6):4393-4402. PubMed ID: 32459969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A carrier-free nanovaccine combined with cancer immunotherapy overcomes gemcitabine resistance.
    Pan W; Wang Y; Chen G; Ma X; Min Y
    Biomaterials; 2025 Feb; 313():122788. PubMed ID: 39236628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-adjuvant Astragalus polysaccharide-based nanovaccines for enhanced tumor immunotherapy: a novel delivery system candidate for tumor vaccines.
    Li N; Zhang Y; Han M; Liu T; Wu J; Xiong Y; Fan Y; Ye F; Jin B; Zhang Y; Sun G; Sun X; Dong Z
    Sci China Life Sci; 2024 Apr; 67(4):680-697. PubMed ID: 38206438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy and Prevention of Cancer by Nanovaccines Loaded with Whole-Cell Components of Tumor Tissues or Cells.
    Ma L; Diao L; Peng Z; Jia Y; Xie H; Li B; Ma J; Zhang M; Cheng L; Ding D; Zhang X; Chen H; Mo F; Jiang H; Xu G; Meng F; Zhong Z; Liu M
    Adv Mater; 2021 Oct; 33(43):e2104849. PubMed ID: 34536044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanovaccine loaded with poly I:C and STAT3 siRNA robustly elicits anti-tumor immune responses through modulating tumor-associated dendritic cells in vivo.
    Luo Z; Wang C; Yi H; Li P; Pan H; Liu L; Cai L; Ma Y
    Biomaterials; 2015 Jan; 38():50-60. PubMed ID: 25457983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-pronged anti-cancer nanovaccines enpowered by exogenous/endogenous tumor-associated antigens.
    Yin M; Liu Z; Zhou Y; Li W; Yan J; Cao D; Yin L
    J Control Release; 2024 Sep; 373():358-369. PubMed ID: 39009083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer Cell Membrane-Coated Adjuvant Nanoparticles with Mannose Modification for Effective Anticancer Vaccination.
    Yang R; Xu J; Xu L; Sun X; Chen Q; Zhao Y; Peng R; Liu Z
    ACS Nano; 2018 Jun; 12(6):5121-5129. PubMed ID: 29771487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Facile preparation of a metal-phenolic network-based lymph node targeting nanovaccine for antitumor immunotherapy.
    Su Q; Liu Z; Du R; Chen X; Chen L; Fu Z; Luo X; Yang Y; Shi X
    Acta Biomater; 2023 Mar; 158():510-524. PubMed ID: 36603733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimalist Nanovaccine with Optimized Amphiphilic Copolymers for Cancer Immunotherapy.
    Niu L; Miao Y; Cao Z; Wei T; Zhu J; Li M; Bai B; Chen L; Liu N; Pan F; Zhu J; Wang C; Yang Y; Chen Q
    ACS Nano; 2024 Jan; 18(4):3349-3361. PubMed ID: 38230639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-Adjuvanting Polyguanidine Nanovaccines for Cancer Immunotherapy.
    Zhang X; Wang K; Zhao Z; Shan X; Wang Y; Feng Z; Li B; Luo C; Chen X; Sun J
    ACS Nano; 2024 Mar; 18(9):7136-7147. PubMed ID: 38407021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leveraging β-Adrenergic Receptor Signaling Blockade for Improved Cancer Immunotherapy Through Biomimetic Nanovaccine.
    Yang C; He Y; Chen F; Zhang F; Shao D; Wang Z
    Small; 2023 Apr; 19(14):e2207029. PubMed ID: 36703529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.